BR112012022052B1 - Uso de dextrometorfano ou dextorfano e uso de dextrometorfano e dextrofano e gabapentina - Google Patents

Uso de dextrometorfano ou dextorfano e uso de dextrometorfano e dextrofano e gabapentina Download PDF

Info

Publication number
BR112012022052B1
BR112012022052B1 BR112012022052-7A BR112012022052A BR112012022052B1 BR 112012022052 B1 BR112012022052 B1 BR 112012022052B1 BR 112012022052 A BR112012022052 A BR 112012022052A BR 112012022052 B1 BR112012022052 B1 BR 112012022052B1
Authority
BR
Brazil
Prior art keywords
symptoms
dextromethorphan
hot flashes
hormonal
sub
Prior art date
Application number
BR112012022052-7A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012022052A2 (pt
Inventor
George E. Royster Jr.
Original Assignee
Fervent Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fervent Pharmaceuticals, Llc filed Critical Fervent Pharmaceuticals, Llc
Publication of BR112012022052A2 publication Critical patent/BR112012022052A2/pt
Publication of BR112012022052B1 publication Critical patent/BR112012022052B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012022052-7A 2010-03-02 2011-03-01 Uso de dextrometorfano ou dextorfano e uso de dextrometorfano e dextrofano e gabapentina BR112012022052B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30963810P 2010-03-02 2010-03-02
US61/309,638 2010-03-02
PCT/US2011/026650 WO2011109367A2 (en) 2010-03-02 2011-03-01 Methods and compositions for treating or preventing symptoms of hormonal variations

Publications (2)

Publication Number Publication Date
BR112012022052A2 BR112012022052A2 (pt) 2020-07-07
BR112012022052B1 true BR112012022052B1 (pt) 2021-06-29

Family

ID=44531862

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022052-7A BR112012022052B1 (pt) 2010-03-02 2011-03-01 Uso de dextrometorfano ou dextorfano e uso de dextrometorfano e dextrofano e gabapentina

Country Status (12)

Country Link
US (1) US20110218213A1 (enExample)
EP (1) EP2542241B1 (enExample)
JP (1) JP5839362B2 (enExample)
CN (1) CN102858343B (enExample)
AU (3) AU2011223807B2 (enExample)
BR (1) BR112012022052B1 (enExample)
CA (1) CA2828041C (enExample)
EA (1) EA027350B1 (enExample)
ES (1) ES2574210T3 (enExample)
IL (2) IL221706A (enExample)
PL (1) PL2542241T3 (enExample)
WO (1) WO2011109367A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9616123B1 (en) * 2012-03-05 2017-04-11 Robert L. Knobler Method and compound for treatment of menopausal symptoms
US11147856B2 (en) * 2015-04-07 2021-10-19 Meiji Co., Ltd. Hot flash-suppressing agent
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
KR20220010721A (ko) * 2019-04-22 2022-01-26 로버트 엘. 노블러 안면 홍조의 비-호르몬 치료
WO2021108801A2 (en) * 2019-11-15 2021-06-03 Consegna Pharma, Inc. Long acting nmda antagonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
EP2275089A1 (en) * 1993-11-19 2011-01-19 Alkermes Controlled Therapeutics, Inc. Preparation of biodegradable microparticles containing a biologically active agent
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6310098B1 (en) * 1999-07-22 2001-10-30 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6569471B2 (en) * 2000-09-01 2003-05-27 Natumin Pharma Ab Method for the treatment of symptoms related to normal hormonal variations in women
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
WO2003037334A1 (en) * 2001-10-31 2003-05-08 Merck & Co., Inc. Method for treating or preventing symptoms of hormonal variation including hot flashes
RU2340333C2 (ru) * 2002-08-15 2008-12-10 Вайет Агонизм 5нт2a -рецептора для лечения нарушения функции терморегуляции
HUP0303313A2 (hu) * 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JP2007537232A (ja) * 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ
WO2005120523A1 (en) * 2004-06-04 2005-12-22 Mood Management Sciences, Llc Methods and compositions for treating mood disorder
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
CA2614244A1 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and an antidepressant
WO2007070779A2 (en) * 2005-12-13 2007-06-21 Trinity Laboratories, Inc. A method to treat premature ejaculation in humans
KR20080097443A (ko) * 2006-02-03 2008-11-05 아바니르 파마슈티컬스 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
CN101677971A (zh) * 2007-03-19 2010-03-24 阿卡蒂亚药品公司 5-ht2a反向激动剂和拮抗剂与抗精神病药物的组合
AU2009274022B2 (en) * 2008-07-22 2016-06-02 Menogenix, Inc. Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis

Also Published As

Publication number Publication date
EA027350B1 (ru) 2017-07-31
EP2542241A2 (en) 2013-01-09
EP2542241A4 (en) 2013-11-06
AU2018205147A1 (en) 2018-08-02
IL253853A0 (en) 2017-09-28
JP2013521297A (ja) 2013-06-10
ES2574210T3 (es) 2016-06-15
WO2011109367A3 (en) 2011-12-29
IL253853B (en) 2019-05-30
US20110218213A1 (en) 2011-09-08
PL2542241T3 (pl) 2016-12-30
CA2828041A1 (en) 2011-09-09
AU2016213776B2 (en) 2018-04-12
CN102858343A (zh) 2013-01-02
BR112012022052A2 (pt) 2020-07-07
AU2011223807B2 (en) 2016-05-12
WO2011109367A4 (en) 2012-02-23
CN102858343B (zh) 2015-11-25
WO2011109367A2 (en) 2011-09-09
AU2011223807A1 (en) 2012-10-18
JP5839362B2 (ja) 2016-01-06
EA201290851A1 (ru) 2013-04-30
CA2828041C (en) 2018-04-17
IL221706A (en) 2017-08-31
EP2542241B1 (en) 2016-04-27
AU2016213776A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
US9457022B2 (en) Methods and compositions for treating or preventing symptoms of hormonal variations
US8420624B2 (en) Methods for treating or preventing symptoms of hormonal variations
AU2016213776B2 (en) Methods and compositions for treating or preventing symptoms of hormonal variations
KR20120058457A (ko) 근육감소증의 예방 및 치료
CN1674880A (zh) 用于治疗体温调节机能障碍的5HT2a受体的激动作用
HU229150B1 (hu) Gyorsan ható szelektív szerotonin-újrafelvételt gátlókat alkalmazó eljárások nemi mûködési zavarok kezelésére
BR112019011743A2 (pt) composições farmacêuticas para o uso no tratamento de dor neuropática periférica e seu processo de preparação
TW200412240A (en) Use for norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
CA2502027A1 (en) A method of treating vasomotor symptoms comprising a compound having norepinephrine reuptake inhibitor activity and 5-ht2a antagonistic activity
ES2625142T3 (es) Usos terapéuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]-piperacina
BR112019016565A2 (pt) Tratamento de emergência de náuseas e vômitos pós-operatórios
RU2768875C2 (ru) Композиции для лечения и профилактики вазомоторных симптомов
US9339500B2 (en) Methods of treating vasomotor symptoms
CN116157127A (zh) 化合物用于治疗口干燥症的用途
JP2019073493A (ja) ヴルヴォディニアの治療
CN111465395A (zh) 治疗或预防血管舒缩症状的组合物和方法
JP2007515395A (ja) 血管運動症状の治療方法
Leong et al. Treating recurrent postmenopausal vasomotor symptoms in a patient with a positive family history for breast cancer
CN101189043A (zh) 肾上腺素能α2B拮抗剂用于治疗血管舒缩症状的应用
CN1705475A (zh) 通过具有去甲肾上腺素重摄取抑制剂活性和5－ht2a拮抗活性的化合物治疗血管舒缩症的方法

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/03/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.